2025

• 03Entered into an agreement with Hyundai Pharm for strategic investment and joint research and development

2024

• 12Initiated phase I clinical trial of AD1208
• 04Disclosed preclinical research findings for AVS1001 project at the American Association for Cancer Research (AACR 2024)
• 04Closed series B financing (17 billion Korean Won)

2023

2022

• 07Completed Series A Financing (10 billion Korean Won)
• 03Opened Research Center and started in-house drug discovery and development
• 02Completed seed investment from Myriad Lifesciences and Infobank
• 02Moved to new headquarter at Magok-dong in Seoul

2021

• 12Closed the collaboration and licensing agreement for AVS1001 with a Research Institute in UK
• 09Avelos Therapeutics was established on September 1st in 2021